Status:
COMPLETED
The Use of Quetiapine (Seroquel) in the Treatment of Social Phobia: Public Speaking Environment
Lead Sponsor:
University of Minnesota
Collaborating Sponsors:
AstraZeneca
Conditions:
Social Phobia
Eligibility:
All Genders
18-25 years
Phase:
PHASE4
Brief Summary
This is a pilot study that will focus on the collection of preliminary data to determine the efficacy of quetiapine for individuals with social phobia. We hypothesize that individuals will react with ...
Detailed Description
Primary Objective: The purpose of this study is to evaluate the use of quetiapine to diminish cue reactivity to a Virtual Reality environment for individuals with Social Phobia. The following primary...
Eligibility Criteria
Inclusion
- Age 18-25
- Primary DSM-IV Axis I diagnosis of social phobia, specific fear of public speaking
- PRCS total score: 21 or greater (1 SD above population norm of 14.2)
Exclusion
- Current contraindications/sensitivity to quetiapine
- Current prescription of benzodiazepine, tranquilizer, or antipsychotic medication
- Current Psychotic episode
- Current Manic episode
- Current Depressive episode
- Current drug or alcohol dependence
- A patient with diabetes mellitus (DM) fulfilling one of the following criteria:
- Unstable DM defined as enrollment glycosylated hemoglobin (HbA1c) 8.5%.
- Admitted to hospital for treatment of DM or DM related illness within the past 12 weeks
- Not under physician care for DM.
- Physician responsible for patient's DM care has not indicated that the patient's DM is controlled.
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2007
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00407199
Start Date
December 1 2006
End Date
September 1 2007
Last Update
October 27 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Minnesota
Minneapolis, Minnesota, United States, 55454